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Introduction: Matrix metalloproteinases (MMPs) and ‘aggrecanase’ a disintegrin and metalloproteinase
with thrombospondin motifs (ADAMTSs) are well established to play key roles in osteoarthritis (OA)
through degradation of extracellular matrix (ECM) type II collagen and aggrecan, and are thus potential
targets for development of OA therapies.
Objective: This paper aims to provide a comprehensive review of the expression and potential roles
of other, lesser-known ADAMTSs and related adamalysins (or a disintegrin and metalloproteinases
(ADAMs)) in cartilage, with a view to identifying potentially protective or homeostatic metal-
loproteinases in the joint and informing consequent selective inhibitor design.
Design: A comprehensive literature search was performed using PubMed terms ‘osteoarthritis’ and
‘ADAMTS’ or ‘ADAM’.
Results: Several ADAMTSs and ADAMs were identiﬁed as having reportedly increased expression in OA.
These include enzymes likely to play roles in cartilage matrix anabolism (e.g., the procollagen N-pro-
teinases ADAMTS-2, ADAMTS-3 and ADAMTS-14), chondrocyte differentiation and proliferation (e.g.,
ADAM9, ADAM10, ADAM12), as well as enzymes contributing to cartilage catabolism (e.g., Cartilage
oligomeric protein (COMP)-degrading ADAMTS-7 and ADAMTS-12).
Conclusions: In addition to the well-characterised MMPs, ADAMTS-4 and ADAMTS-5, many other
ADAMTSs and ADAMs are expressed in cartilage and several show signiﬁcantly altered expression in OA.
Studies aimed at elucidating the pathophysiological roles of these enzymes in cartilage will contribute to
our understanding of OA pathogenesis and enable design of targeted inhibitors that effectively target
metalloproteinase-mediated cartilage degradation while sparing cartilage repair pathways.
© 2017 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Osteoarthritis (OA) is a common degenerative joint disease
characterised by cartilage loss, subchondral bone remodelling
and osteophyte development. These structural changes are
accompanied by impaired movement, stiffness and chronic joint
pain. Primary risk factors for OA include age, obesity and
joint injury, which alter the mechanical loading of the joint and
initiate dysregulated cellular signalling and activation of catabolic
pathways.
The role of matrix metalloproteinases (MMPs) in osteoar-
thritic degradation of the extracellular matrix (ECM) has been. Troeberg, Kennedy Institute
ve, OX3 7FY Oxford, UK.
L. Troeberg).
r Ltd on behalf of Osteoarthritis Rewell documented. In particular, the collagenase matrix metal-
loproteinase 13 (MMP-13) plays a central role in degrading type
II collagen1,2, and the two ‘aggrecanases’, namely a disintegrin
and metalloproteinase with thrombospondin motifs (ADAMTS)-4
and -5, degrade aggrecan3,4. Collagen and aggrecan are the pri-
mary structural components of the cartilage ECM, and their
degradation correlates with progression of OA. Collagenases and
aggrecanases are thus potential targets for the development of
disease-modifying OA drugs (DMOADs). For such an approach to
be successful, it is vital that we learn lessons from previous at-
tempts to develop metalloproteinase inhibitors as anti-cancer
therapies5. These drugs failed due to limited speciﬁcity and
consequent off-target inhibition of other metalloproteinases with
homologous catalytic domains. Only by understanding the full
spectrum of metalloproteinases expressed in the joint and their
biological function(s) in this location will it be possible to designsearch Society International. This is an open access article under the CC BY license
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Several ADAMTSs other than ADAMTS-4 and -5 are expressed in
cartilage, but little is known about whether they are required for
joint health or whether they contribute to OA pathogenesis. The
roles of the related adamalysin (a disintegrin and metal-
loproteinase, ADAM) family of metalloproteinases in cartilage are
similarly poorly understood. Here, we review studies examining
the role of ADAMTSs and ADAMs in cartilage, and compare
microarray studies examining their expression in murine models
of OA6e8 and human normal and osteoarthritic cartilage9e17.
This review thus highlights ADAMTSs and ADAMs that are
expressed in cartilage and whose expression is altered in OA,
with a view to developing a broader understanding of the
contribution of the metalloproteinase family to joint health and
disease.
ADAMTSs
The ADAMTSs are a family of 19 secreted metalloproteinases
(Fig. 1) involved in various developmental and homeostatic
processes18. The ‘aggrecanases’ ADAMTS-4 and -5 have been
extensively reviewed elsewhere19,20, and will not be covered here.
Several other ADAMTSs are expressed in cartilage, and have
emerging roles in joint pathophysiology.Fig. 1. Schematic representation of ADAM and ADAMTS topography. ADAMs and ADAMTSs a
the MMPs, and contain a zinc ion (red circle) that is essential for their proteolytic activity. All t
until they are activated. The families differ in their C-terminal ancillary domains, which me
contain C-terminal disintegrin-like domains, thought to regulate cellecell and cellematrix
cytoplasmic domains are the most diverse, and vary in sequence and length. Some ADAM cy
indicating that theymayparticipate in intracellular signalling. Some also containpotential seri
conveying signals between the cell and its surroundings. ADAMTS ancillary domains: In contras
cytoplasmic domains. In addition to their catalytic and pro-domains, the enzymes contain
homologous to thrombospondins18, as well as a cysteine-rich domain and spacer domain.
ADAMTS-9 and -20 contain GON-1 domains, ADAMTS-2, -3 and -14 contain a procollagen N-ADAMTS-1
ADAMTS-1 is expressed in cartilage and synovium18 and has
been shown to cleave aggrecan and versican21. Several studies
show that ADAMTS-1 expression is signiﬁcantly upregulated in OA
cartilage7,10e12,14,22, though some studies indicate reduced expres-
sion in late-stage human OA9,13,17 (Fig. 2). Immunohistochemical
analysis indicates that in normal cartilage, ADAMTS-1 is primarily
expressed in the superﬁcial zone, with OA cartilage showing
increased staining in the middle zone and in osteophytes22.
Adamts1-null mice display unaltered susceptibility in the
antigen-induced model of inﬂammatory arthritis and there is also
no change in the level of aggrecan degradation in response to
interleukin 1 (IL-1) stimulation of cartilage explants in vitro23. The
susceptibility of these mice to surgical destabilisation of the medial
meniscus (DMM), a model that more closely resembles human OA,
has not been reported. Given that Adamts1-null mice show devel-
opmental abnormalities24, conditional deletion may be required to
establish the role of the enzyme in cartilage homeostasis.
ADAMTS-2, ADAMTS-3 and ADAMTS-14
ADAMTS-2, ADAMTS-3 and ADAMTS-14 are procollagen N-pro-
teinases, responsible for removing the N-terminal propeptide ofre metzincin metalloproteinases whose catalytic domains share homology with those of
hree groups of enzymes have a prodomain that keeps them in an inactive zymogen form
diate interaction with substrates and other proteins. ADAM ancillary domains: ADAMs
adhesion, as well as conserved cysteine-rich domains and EGF-like domains102. The
toplasmic domains contain proline-rich Src homology (SH)-2 and/or SH-3 binding sites,
neethreonine and/or tyrosine phosphorylation sites,making themplausible adaptors for
t to the ADAMs, ADAMTSs are secretedmetalloproteinases that lack transmembrane and
a variable number of thrombospondin type 1 sequence repeat (TSR) motifs, which are
Some members of the family contain additional C-terminal domains18. For example,
propeptidase (PNP) domain, and ADAMTS-7 and -12 contain a PLAC domain.
Fig. 2. Fold-change in expression of ADAMTSs and ADAMs in OA compared to normal cartilage. Upregulated genes are marked in red (statistically signiﬁcant, P < 0.05) or pink (not
statistically signiﬁcant, P > 0.05), while down-regulated genes are shown in dark blue (statistically signiﬁcant, P < 0.05) or light blue (not statistically signiﬁcant, P > 0.05). Bateman6,
Gardiner7 and Loeser8 analysed murine knee cartilage at various time points after DMM. Sato15, Geyer11, Dunn10, Ramos14, and Snelling16 analysed paired samples from intact and
OA lesion areas of the same patients. Karlsson12 compared knee OA samples with healthy controls. Swinger17, Kevorkian13 and Davidson9 compared femoral head cartilage from OA
patients with that of fracture patients. Syn, synovium.
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ﬁbril formation. Lack of procollagen N-proteinase activity is asso-
ciated with defective collagen ﬁbrilogenesis and connective tissue
dysfunctions such as skin fragility26. Since type II collagen is a
critical structural component of the cartilage ECM, these enzymes
are likely to be important for cartilage homeostasis and repair.
Bekhouche et al.28 recently identiﬁed additional substrates for this
group of enzymes, including several proteins involved in trans-
forming growth factor b (TGFb) signalling.
Several studies indicate statistically signiﬁcant increased
expression of ADAMTS-2 in OA cartilage7e10,12,13,17. No cartilage or
joint abnormalities have been identiﬁed in Adamts2-deﬁcientmice26, although they exhibit skin fragility reminiscent of Ehlers-
Danlos syndrome in humans, which is also caused by mutation of
ADAMTS-2. Partial processing of collagen in these mice appears to
indicate some redundancy between the procollagen N-proteinases.
ADAMTS-3 is more potent than ADAMTS-2 at processing type II
pro-collagen29, suggesting that it may be more relevant than
ADAMTS-2 in cartilage. As with ADAMTS-2, ADAMTS-3 expression
is reportedly increased in OA cartilage8,9, although this reaches
statistical signiﬁcance in fewer studies than ADAMTS-2, and Dunn
et al.10 report a reduction in expression in late stage human OA
cartilage. Adamts3 knockout mice are not viable after E15.030, so
generation of conditional knockout mice will be necessary to
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and OA pathogenesis.
ADAMTS-14, the third of the procollagen N-proteinases to be
discovered31, is also signiﬁcantly up-regulated in human OA carti-
lage9,10,13,17. Single nucleotide polymorphisms (SNPs) of ADAMTS14
have been associated with an increased risk of knee OA in two fe-
male cohorts32,33. The enzyme may be differently regulated in
murine OA models, since little regulation is observed in most mu-
rinemicroarray studies, other than reduced expression observed by
Bateman et al.6 1 week after surgical induction of OA in mice.
The increased expression of all three of these enzymes in human
OA cartilage may reﬂect an attempted anabolic repair response of
osteoarthritic chondrocytes, and it would be desirable to spare
these enzymes when designing metalloproteinase inhibitors for
potential OA therapy.
ADAMTS-7 and ADAMTS-12
ADAMTS-734 and ADAMTS-1235 are thought to contribute to OA
pathogenesis by degrading cartilage oligomeric protein (COMP), an
important regulator of cartilage ECM assembly and a potential
biomarker for cartilage degradation.
Several studies have observed increased expression of ADAMTS-
7 in OA cartilage9,17,23,36e38. OA progression and COMP degradation
were increased in mice over-expressing ADAMTS-7 and decreased
in Adamts7/ mice37. COMP degradation could also be inhibited
in vitro by addition of ADAMTS-7 neutralising antibodies or
siRNA39. Expression of the enzyme can be stimulated by pro-
inﬂammatory cytokines such as tumour necrosis factor (TNF)39. A
positive feedback loop has been proposed between ADAMTS-7 and
TNF, since TNF expression is elevated in transgenic mice over-
expressing ADAMTS-7 in chondrocytes37. The molecular mecha-
nism underpinning this feedback loop is not known.
Increased expression of ADAMTS-12 is also consistently observed
in OA cartilage7e10,13,17,35,38. COMP degradation in OA cartilage ex-
plants couldbeadditively inhibited byneutralising antibodies against
ADAMTS-7 and ADAMTS-1239, suggesting that ADAMTS-12 may also
contribute to pathological COMP degradation. These enzymes may
alsowork together to process substrates in vivo. Systematic analysis of
single and combinedAdamts7-andAdamts12-nullmicewould help to
clarify the relative contributions these enzymes make to COMP
degradation in OA.
ADAMTS-8
ADAMTS-8 is expressed in normal cartilage and has been re-
ported to have aggrecanase activity40. Expression of the enzyme in
cartilage is not signiﬁcantly altered in murine models of OA,7,15
although Davidson et al.9 reported increased expression in human
OA synovium.
ADAMTS-9 and ADAMTS-20
ADAMTS-9 and ADAMTS-20 are the largest members of the
ADAMTS family, with 15 thrombospondin domains and a C-ter-
minal GON-1 domain.
ADAMTS-9 is expressed in normal cartilage, and highly
induced in response to pro-inﬂammatory cytokines (e.g., IL-1b
and TNF41) and adipokines (e.g., leptin42). Expression is reduced in
late-stage OA cartilage9,13,17. ADAMTS-9 is able to cleave aggrecan,
although a truncated form of the enzyme (comprising the cata-
lytic, disintegrin and ﬁrst TS domain) exhibits low aggrecanase
activity compared to a similarly truncated form of ADAMTS-543. It
is not known whether the full-length enzyme has higheraggrecanase activity, since this large enzyme is difﬁcult to express
and purify.
ADAMTS-20 is expressed in cartilage and reportedly shows
increased expression in OA9, but the enzyme is primarily consid-
ered to be important for versican cleavage during development.
ADAMTS-15
ADAMTS-15 is also thought to participate in developmental
versican cleavage44, but is expressed in cartilage and can cleave
aggrecan45. Threemicroarray studies found increased expression of
ADAMTS-15 in OA cartilage7,9,17, while two10,13 found reduced
expression. The contribution of the enzyme to cartilage homeo-
stasis and disease is unknown.
ADAMTS-16
ADAMTS-16 expression is increased in OA cartilage7,9,13,17 and a
truncated form of the enzyme shows some aggrecanase activity43.
To our knowledge, the aggrecanase activity of the full-length
enzyme has not been characterised. Surridge et al.46 observed
that over-expression of ADAMTS-16 in SW1353 chondrosarcoma
cells decreasedMMP13 expression, cell migration and proliferation,
raising the possibility that ADAMTS-16 may have a protective role.
Mechanistic investigation of these observations may shed light on
the role of this enzyme in cartilage.
Other ADAMTSs
Microarray studies have reported increased expression of
ADAMTS-614e17, ADAMTS-109, and ADAMTS-189,17 in OA cartilage.
These are ‘orphan’ enzymes without known substrates. Studies
on their wider biological functions have implicated ADAMTS-6 and
-10 in regulations of cellecell junctions47 and ADAMTS-18 in
development48.
ADAM metalloproteinases
The A Disintegrin andMetalloproteinase (ADAM, or adamalysin)
family are conserved type-I transmembrane metzincin metal-
loproteinases related to the MMPs and ADAMTSs (Fig. 1). ADAMs
are widely expressed and have been shown to participate in a wide
variety of biological processes49,50.
Among the 34 known ADAMs, 20 are present in the human
genome and 12 of these (ADAM8, ADAM9, ADAM10, ADAM12,
ADAM15, ADAM17, ADAM19, ADAM20, ADAM21, ADAM28,
ADAM30 and ADAM33) are predicted to be proteolytically active
based on the presence of a conserved HEXGHXXGXXHD motif and
downstream ‘Met turn’ in the catalytic domain49. The proteolyti-
cally active ADAMs mainly function as ‘sheddases’, cleaving the
juxta-membrane region of their trans-membrane substrates
(reviewed by Edwards et al.49) to release the soluble ectodomain of
the substrate to the extracellular space. This activity enables them
to regulate the extracellular availability of autocrine and paracrine
signallingmolecules, such as transmembrane cytokines and growth
factors and their receptors. The remaining eight human ADAMs
(ADAM2, ADAM7, ADAM11, ADAM18, ADAM22, ADAM23, ADAM29,
ADAM32) are predicted to lack proteolytic activity, but still play
important biological roles49.
The roles of ADAMs in development of the musculoskeletal
system have been well documented, and the roles of some of the
ADAMs in rheumatoid arthritis have been examined. The roles of
these enzymes in adult joint tissues and in OA have been less well
characterised. We review the emerging evidence for roles of these
enzymes in joint homeostasis and OA pathogenesis.
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Expression of ADAM8 is reportedly elevated in human OA
cartilage17,51,52, and the enzyme has been postulated to contribute
to OA pathogenesis by cleaving ﬁbronectin and generating cryptic
pro-catabolic ﬁbronectin fragments52. Zack et al.52 showed that
addition of recombinant ADAM8 to human OA cartilage explants
increases aggrecan cleavage and cartilage degradation in vitro.
Expression of ADAM8 was signiﬁcantly reduced 6 weeks after
surgical induction of OA in a murine model6, indicating either
species-speciﬁc differences in regulation or that the enzyme is
dynamically regulated during OA progression.
ADAM8 is also expressed in cells of the mononuclear phagocyte
lineage53. ADAM8 promotes osteoclast formation54,55 and is
thought to contribute to the bone erosion associated with aseptic
loosening of hip replacement prostheses56. Increased expression of
ADAM8 has been observed in rheumatoid arthritis pannus tissue55,
suggesting that ADAM8may also contribute to osteoclast formation
and bone erosion in rheumatoid arthritis.
ADAM9 (meltrin-Ɣ)
Several studies consistently report signiﬁcant upregulation of
ADAM9 in human OA cartilage10,12,17 and the enzyme is non-
signiﬁcantly upregulated in mice 2 weeks after DMM surgery7.
ADAM9 substrates include growth factor precursors49, and the
enzyme has been suggested to play a role in chondrogenesis57. Its
expression is decreased in response to IL-1 or retinoic acid58.
Reminiscent of ADAM8, ADAM9 is expressed in mononuclear
phagocytes and osteoclasts, and has been suggested to contribute
to bone resorption associated with aseptic loosening of hip
prostheses59.
ADAM10
ADAM10 is one of the best characterised of the ADAMs, and is
crucial for embryonic development through its shedding of Notch
receptor and consequent regulation of downstream Notch signal-
ling49. ADAM10 also has pivotal roles in cell migration and adhe-
sion, mediated through its cleavage of transmembrane precursors
of growth factors (e.g., epidermal growth factor, EGF), chemokines
(e.g., CX3CL1 and CXCL16) and adhesionmolecules (e.g., E-cadherin
and VE-cadherin)49.
Expression of ADAM10 is low in normal adult cartilage, but
increased during development60, in OA7,10,60 and in response to
pro-inﬂammatory cytokines60,61. In OA or IL-1a-stimulated carti-
lage, highest expression of ADAM10 was observed in regions with
greatest damage and proteoglycan loss60, leading Chubinskaya
et al.60 to suggest the enzyme may contribute to cartilage damage.
ADAM10 substrates in normal or OA cartilage have not been
characterised.
ADAM10 expression is also increased in synovium lining and
endothelial cells of rheumatoid arthritis patients61. Silencing of
ADAM10 in endothelial cells reduced migration and tubule for-
mation, suggesting the enzyme may contribute to angiogenesis in
the rheumatoid synovium61.
ADAM12 (meltrin-a)
ADAM12 is the ADAM most consistently reported to display
increased expression in human OA cartilage10e12,15e17,62. Its expres-
sion is reported to correlate with Mankin score62, and increased
expression has also been reported in mice 2 weeks after DMM sur-
gery7. Several studies have linked ADAM12 SNPs (e.g., rs1278279,
rs3740199, rs1044122, and rs1871054) with an increased risk ofOA63e70, although post-hoc stratiﬁcation of data was often required
to establish a signiﬁcant association. A large case-controlled study of
over 1000 UKOA patients and an equal number of matched controls
failed to ﬁnd any association between ADAM12 SNPs and OA71.
Substrates of ADAM12 in cartilage have not been directly
investigated. The enzyme is widely expressed and has been shown
to promote cell proliferation, differentiation andmigration through
its ability to shed transmembrane ligands of the EGF receptor and
thus stimulate EGF receptor signalling72. ADAM12 also modulates
insulin-like growth factor (IGF) signalling by cleavage of IGF bind-
ing proteins72. ADAM12 has similarly been shown to promote
chondrocyte proliferation and maturation during develop-
ment62,73, although it is proposed to act by promoting IGF-1 activity
by degrading IGF binding protein 562, rather than by an EGF
receptor-dependent pathway.
ADAM15 (Metargidin)
ADAM15 is the only ADAM so far demonstrated to have a pro-
tective role in cartilage, with Adam15-deﬁcient mice developing
accelerated spontaneous OA with age74. Bohm et al. reported that
expression of the enzyme is increased in OA cartilage using in situ
hybridisation75, but subsequent microarrays have reported either
no change7 or slight but statistically non-signiﬁcant increased
expression in OA10,17.
Understanding of how ADAM15 protects cartilage is still in its
infancy. B€ohm et al. proposed that ADAM15 increases chondrocyte
survival by reinforcing adhesion to collagen types II and VI74, pro-
moting outside-in pro-survival signalling76,77 and up-regulating
anti-apoptotic molecules such as X-linked inhibitor of apoptosis
(XIAP)78.
ADAM15 has been shown to affect cellecell and cellematrix
adhesion in other cell types79e81, potentially also through its ability
to interact with integrins. ADAM15 is the only ADAM that contains
an integrin-binding Arginine-glycine-aspartic acid (RGD) motif in
its disintegrin domain82, enabling RGD-dependent interactionwith
avb3 and a5b183, and ADAM15 is also able to bind to a9b3 in an RGD-
independent manner84. ADAM15 over-expression been shown to
promote migration of mesangial cells85, possibly by disrupting
integrin-ECM interactions or by proteolytic cleavage of adhesion
molecules. N- and E-cadherin86,87 are among the few ADAM15
substrates described, and their degradation may underpin the ef-
fect of ADAM15 on cell migration. The relevance of these studies to
ADAM15's protective role in cartilage is unclear, especially since
many were done using overexpression systems that may not
accurately reﬂect the physiological activity of the enzyme.
It is not yet known how these different activities of ADAM15 are
regulated or coordinated. Additionally, ADAM15 substrates in
chondrocyte have not been identiﬁed. Further studies to investigate
the protective role of this enzyme in the joint are required.
ADAM17 (TNF-a-converting enzyme, TACE)
ADAM17, or TACE, is the most extensively studied ADAM, with
important roles in development and inﬂammation through its
shedding of EGF receptor ligands and the membrane-bound pre-
cursor of the pleiotropic cytokine TNF88.
ADAM17 deletion leads to perinatal lethality, so conditional and
tissue-speciﬁc deletion have been studied to evaluate the function
of the enzyme in speciﬁc tissues and in the adult. Deletion of
ADAM17 in chondrocytes retarded expansion of hypertrophic
chondrocytes in the growth plate and impaired bone growth89,90.
This indicates that ADAM17 is important for musculoskeletal
development, most likely through its role in EGF receptor
signalling.
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chondrocyte-speciﬁc inducible knockout of ADAM17 has not been
reported, so the role of the enzyme in adult cartilage is not known.
Microarray studies indicate that ADAM17 expression is not signif-
icantly altered in OA7,10,17, but such studies do not take account
of the fact that ADAM17 activity is largely regulated post-
translationally.
Oldefest et al.91 showed that ADAM17 shedding of the IL-6 re-
ceptor (IL-6R) can be inhibited by secreted Frizzled-related protein
3 (sFRP3), but not by variants of sFRP3 that have previously been
associated with an increased risk of OA. This raises the possibility
that the sFRP3 variants promote cartilage damage by failing to
control ADAM17 pro-inﬂammatory activity in cartilage.
ADAM19
ADAM19 is expressed during chondrogenesis, with increased
expression during the later stages of the process57. Expression of
the enzyme is reportedly not signiﬁcantly altered in OA
cartilage10,17.
ADAM23
Like ADAM19, ADAM23 is also up-regulated at the late stage of
chondrogenesis57,92. ADAM23 is up-regulated in OA cartilage17, but
its function in cartilage has not been investigated.
ADAM28
ADAM28 is expressed at low levels in normal cartilage, with
increased expression in OA17. The enzyme has been suggested to
promote retinoic acid-stimulated proteoglycan degradation93,
although the molecular mechanism for this observation has not
been established. Known substrates of ADAM28 include TNF94 and
growth factors such as IGF binding protein-395 and connective
tissue growth factor (CTGF)96. In osteoblasts, IL-1b-induced MMP-
13 expression is dependent on ADAM2897, suggesting the enzyme
may also affect bone remodelling.
Other ADAMs
Swinger et al.17 report that expression of the ADAM22 and
ADAM33 is increased in OA cartilage, while expression of ADAM2,
ADAM7, ADAM11, ADAM18, ADAM20, ADAM21, ADAM29, ADAM30
and ADAM32 is not signiﬁcantly altered in OA17.
Concluding remarks and future study directions
Collagenases and aggrecanases have received attention as po-
tential targets for development of DMOADs. In order for such an
approach to be successful, we should learn the lessons of previous
attempts to design MMP inhibitors to treat cancer, namely that it is
crucial to understand the full spectrum of metalloproteinases
expressed in a target tissue. Many ADAMTSs and ADAMS are
expressed in cartilage and several are differentially regulated in OA,
but their roles in cartilage health and disease are largely unex-
plored and the full spectrum of their substrates is not yet known.
Further research into the functions and substrates of these enzymes
in the joint and in OA pathogenesis is required to evaluate thera-
peutic potential. Unbiased proteomic analysis will assist in deﬁning
the range of substrates cleaved by each enzyme. Additionally, en-
zymes may be important at different temporal stages in the disease
process, with implications for timing of effective inhibitor therapy.
Inducible knockout strategies may be useful in deﬁning relevant
windows of activity.It is especially important to understand which enzymes may
serve protective functions in the joint, since inhibiting their ac-
tivity is likely to further impair cartilage homeostasis. For
example, the procollagen N-proteinases ADAMTS-2, ADAMTS-3
and ADAMTS-14 are likely to promote matrix anabolism, and
several studies have demonstrated that their expression is
increased in OA. Inducible and combined knockout of these en-
zymes are required to investigate their contribution to cartilage
repair in OA and to investigate potential redundancy among the
enzymes. Similarly, ADAMs play important roles in signalling in
other tissues, and are likely to modulate a diverse range of sig-
nalling pathways in chondrocytes. For example, ADAMs can acti-
vate signalling pathways by mobilising transmembrane cytokine
and growth factor precursors, or through interaction of their
cytoplasmic domains with intracellular signalling machinery.
Conversely, ADAM-mediated shedding of cytokine and growth
factor receptors can suppress their downstream signalling.
ADAMs thus ﬁne-tune cellular responses and contribute to
maintenance of tissue homeostasis, and changes in ADAM
expression may contribute to the shift in balance from cartilage
repair to cartilage degradation. Studies on ADAM15, one of the few
ADAMs to be studied in the context of OA, have shown that
Adam15-null animals develop accelerated OA74, although the
molecular mechanism of this protection is poorly understood.
Increased expression of ADAM9, ADAM10 and ADAM12 in OA
cartilage has been consistently reported in multiple studies. The
activities of these enzymes in other tissues indicate that they may
promote chondrocyte differentiation and proliferation, and so
may contribute to repair pathways in OA, but direct evidence for
this is lacking. Since several of the ADAMs are critically involved in
embryogenesis and development, inducible knockout systems
will be necessary to expand our understanding of their patho-
physiological roles in the joint.
Mechanisms regulating ADAM and ADAMTS expression and
activity in the joint also require further study. Several ADAM and
ADAMTS genes displayed altered methylation in OA. These
included ADAMTS2, ADAMTS8 (hypermethylated in OA) and
ADAMTS4, ADAMTS5, ADAMTS10 and ADAMTS17 (hypomethylated
in OA)98. How these differences in methylation inﬂuence expres-
sion is unclear. Expression is also affected by microRNAs, as has
been reviewed elsewhere99. Additionally, enzymatic activity is
often regulated post-translationally. ADAMTS-4 and -5 are post-
translationally regulated by endocytosis100, and other ADAMTSs
may be similarly regulated. Activity of several ADAMs is also
regulated post-translationally, through mechanisms such as
conformational change, or regulation of substrate or enzyme
localisation101.
It is important to keep in mind that altered expression of
ADAMTSs and ADAMs in OA does not necessarily mean that a
particular enzyme is mechanistically involved in disease patho-
genesis. This is particularly true in late-stage OA, where expres-
sion may be modiﬁed by changes in cell homeostasis or altered
substrate availability occurring due to matrix catabolism. Knock-
out mice studies are required to validate roles in OA pathogen-
esis. Inducible knock-out models will enable analysis of enzyme
functions at different stages of OA progression. Murine studies
are potentially complicated by species differences and the
question of whether acute surgical models accurately reﬂect the
human disease, but they have the advantage of enabling analysis
of early OA, which is difﬁcult to achieve with human clinical
samples.
ADAMTSs and ADAMs have the potential to modulate multiple
aspects of cell behaviour and tissue homeostasis. Understanding
their roles in cartilage is therefore essential for the development of
successful therapies to target osteoarthritic cartilage degradation.
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ECM extracellular matrix
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